HeritX Announces the Appointment of Points Group CEO Thomas Hofstetter to the HeritX Board
FLORHAM PARK, NJ (February 20, 2018) – HeritX announces the appointment of Thomas Hofstetter, Chief Executive Officer (CEO) and Founder of Points Group, to its Board of Trustees.
“We are very pleased to have Thomas Hofstetter join our board and look forward to working together closely,” says Thomas Bock, Chairman and CEO of HeritX. “Thomas is an experienced business leader and entrepreneur who has successfully started and invested in various businesses in the healthcare industry. His expertise and commitment are invaluable for a groundbreaking effort such as our global HeritX initiative on cancer prevention. His contributions will help to further accelerate our life-saving mission.”
Hofstetter established Points Group, an award-winning healthcare consulting and marketing company that offers consulting, marketing and public relations services to a broad spectrum of companies in the healthcare industry. Prior to forming Points Group, he led and formed several entrepreneurial ventures in healthcare, sports and information technology. Hofstetter also co-founded the National Women’s Soccer League (NWSL) in the U.S.
“I’m very excited to join the HeritX board,” states Hofstetter. “I first became involved with HeritX because I was truly inspired and impressed by the revolutionary and innovative approach HeritX is taking towards preventing cancer. There is no other organization that is utilizing their pattern-breaking accelerated roadmap for a solution to cancer.”
Points Group has been engaged with HeritX and its mission of cancer prevention since 2016, providing pro bono marketing and PR services.
To learn more about HeritX or to help achieve cancer prevention, visit www.heritx.org.
HeritX is a nonprofit research and development (R&D) organization driven to prevent cancer, going beyond the treatment of cancer after it has already occurred. HeritX is the only organization worldwide focused solely on the goal of preventing inherited cancers.